Crinetics Pharmaceuticals CRNX has observed the following analyst ratings within the last quarter:

According to 4 analyst offering 12-month price targets in the last 3 months, Crinetics Pharmaceuticals has an average price target of $44.25 with a high of $50.00 and a low of $35.00.

Get a quick summary of 4 analysts' ratings for Crinetics Pharmaceuticals over the last 3 months. More bullish views suggest a positive outlook, while more bearish views imply a negative sentiment.

Highlighting a 14.9% decrease, the current average has fallen from the previous average price target of $52.00.

Analyzing Analyst Ratings: A Detailed Breakdown

Embark on a journey into the analyses of financial experts and analysts, featuring a detailed breakdown of their recent assessments for Crinetics Pharmaceuticals. Our Ratings Table below provides a comprehensive overview of the moves made by key analysts, their present ratings, and price targets. Understanding the perceptions of these experts towards the company can unveil valuable insights into possible market trends and investor sentiment.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crinetics Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Crinetics Pharmaceuticals compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Crinetics Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.

To gain a panoramic view of Crinetics Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Crinetics Pharmaceuticals analyst ratings.

All You Need to Know About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Key Indicators: Crinetics Pharmaceuticals's Financial Health

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

Revenue Challenges: Crinetics Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -24.45%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Crinetics Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -16606.36%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.33%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Crinetics Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.29%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.1, Crinetics Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Basics of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.